1. A compound or a prodrug or a solvate or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula I
wherein
R1 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6 OCONR7R8, OSO2 NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10, and provided that at least one of R1 and R2 is aryl or heteroaryl;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R4 is selected from the group consisting of hydrogen, halogen, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, NR7R8, SR6, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R6 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R7, R8, and R9 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
wherein, any two of R6, R7, R8, and R9 may optionally together form a 4 to 7-membered cycloalkyl, cycloalkenyl or heterocyclyl ring;
R10 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R11;
R11 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R12; and
R12 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7).
2. The compound according to claim 1, wherein R1 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
3. The compound according to claim 1, wherein R2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
4. The compound according to claim 1, wherein R3 is selected from the group consisting of alkyl and alkyl substituted with aryl or heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
5. The compound according to claim 1, wherein:
R1 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10; and
R3 is selected from the group consisting of alkyl and alkyl substituted with aryl or heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
6. The compound according to claim 1, wherein the compound is selected from the group consisting of:
7. A pharmaceutical composition, comprising at least one compound or a prodrug or a solvate or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula I
wherein
R1 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6 OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10, and provided that at least one of R1 and R2 is aryl or heteroaryl;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 3 R10;
R4 is selected from the group consisting of hydrogen, halogen, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, NR7R8, SR6, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R6 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R7, R8, and R9 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
wherein, any two of R6, R7, R8, and R9 may optionally together form a 4 to 7-membered cycloalkyl, cycloalkenyl or heterocyclyl ring;
R10 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R11;
R11 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R12; and
R12 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7); and
at least one pharmaceutically acceptable carrier or diluent.
8. The pharmaceutical composition according to claim 7, further comprising: at least one additional therapeutic agent.
9. A pharmaceutical combination comprising a pharmaceutical composition of claim 7 and a therapeutic agent selected from anti-obesity agents;
appetite suppressants; anti-diabetic agents; anti-hyperlipidemia agents; hypolipidemic agents; hypocholesterolemic agents; lipid-modulating agents; cholesterol-lowering agents; lipid-lowering agents; HDL-raising agent, anti-hypertensive agents; agents used to treat sleep disorders; agents used to treat substance abuse and addictive disorders; anti-anxiety agents; anti-depressants; anti-psychotic agents; cognition enhancing agents; agents used to treat cognitive disorders; agents used to treat Alzheimer’s disease; agents used to treat Parkinson’s disease; anti-inflammatory agents; agents used to treat neurodegeneration; agents used to treat arteriosclerosis; agents used to treat respiratory conditions; agents used to treat bowel disorders; cardiac glycosides; and anti-tumor agents.
10. The pharmaceutical combination according to claim 9 wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of the pharmaceutical composition of claim 7.
11. A method for treating obesity, comprising: administering a therapeutically effective amount of at least one cannabinoid receptor 1 antagonist or a prodrug or a solvate or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula I to a patient in need
wherein
R1 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, SO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10, and provided that at least one of R1 and R2 is aryl or heteroaryl;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 3 R10;
R4 is selected from the group consisting of hydrogen, halogen, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, NR7R8, SR6, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R6 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R7, R8, and R9 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
wherein, any two of R6, R7, R8, and R9 may optionally together form a 4 to 7-membered cycloalkyl, cycloalkenyl or heterocyclyl ring;
R10 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R11;
R11 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7 CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R12; and
R12 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR8R7, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7).
12. A method for smoking cessation, comprising: administering a therapeutically effective amount of at least one cannabinoid receptor 1 antagonist or a prodrug or a solvate or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula I to a patient in need
wherein
R1 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, R6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10, and provided that at least one of R1 and R2 is aryl or heteroaryl;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 3 R10;
R4 is selected from the group consisting of hydrogen, halogen, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, NR7R8, SR6, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R6 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R7, R8, and R9 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
wherein, any two of R6, R7, R8, and R9 may optionally together form a 4 to 7-membered cycloalkyl, cycloalkenyl or heterocyclyl ring;
R10 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R11;
R11 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R12; and
R12 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6 NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7).
13. A compound or a prodrug or a solvate or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula II
wherein
R1 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7 SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6 and CONR7R8, any of which may be optionally substituted with 1 to 3 R10, and provided that at least one of R1 and R2 is aryl or heteroaryl;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 3 R10;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 3 R10;
R6 is selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
R7, R8, and R9 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl and heterocyclyl, any of which may be optionally substituted with 1 to 3 R10;
wherein, any two of R6, R7, R8, and R9 may optionally together form a 4 to 7-membered cycloalkyl, cycloalkenyl or heterocyclyl ring;
R10 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R11;
R11 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7), any of which may be optionally substituted with 1 to 3 R12; and
R12 in each instance is independently selected from the group consisting of aryl, heteroaryl, alkyl, alkenyl, alkynyl, heterocyclyl, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, CONR7R8, halogen, cyano, hydroxyl, carboxyl, and the divalent groups oxo (\u2550O) and oximato (\u2550NOR7).
14. The compound according to claim 13, wherein R1 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
15. The compound according to claim 13, wherein R2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
16. The compound according to claim 13, wherein R3 is selected from the group consisting of alkyl and alkyl substituted with aryl or heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
17. The compound according to claim 13, wherein:
R1 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10;
R2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted with 1 to 3 R10; and
R3 is selected from the group consisting of alkyl and alkyl substituted with aryl or heteroaryl, either of which may be optionally substituted with 1 to 3 R10.
18. The compound according to claim 13, wherein the compound is selected from the group consisting of:
19. A pharmaceutical composition, comprising:
at least one compound according to claim 13; and at least one pharmaceutically acceptable diluent or carrier.
20. The pharmaceutical composition according to claim 19, further comprising: at least one additional therapeutic agent.
21. A pharmaceutical combination comprising a pharmaceutical composition of claim 19 and a therapeutic agent selected from anti-obesity agents; appetite suppressants; anti-diabetic agents; anti-hyperlipidemia agents; hypolipidemic agents; hypocholesterolemic agents; lipid-modulating agents; cholesterol-lowering agents; lipid-lowering agents; HDL-raising agent, anti-hypertensive agents; agents used to treat sleep disorders; agents used to treat substance abuse and addictive disorders; anti-anxiety agents; anti-depressants; anti-psychotic agents; cognition enhancing agents; agents used to treat cognitive disorders; agents used to treat Alzheimer’s disease; agents used to treat Parkinson’s disease; anti-inflammatory agents; agents used to treat neurodegeneration; agents used to treat arteriosclerosis; agents used to treat respiratory conditions; agents used to treat bowel disorders; cardiac glycosides; and anti-tumor agents.
22. The pharmaceutical combination according to claim 21 wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of the pharmaceutical composition of claim 19.
23. A method for treating obesity, comprising: administering a therapeutically effective amount of at least one cannabinoid receptor 1 antagonist according to claim 13 to a patient in need.
24. A method for smoking cessation, comprising: administering a therapeutically effective amount of at least one cannabinoid receptor 1 antagonist according to claim 13 to a patient in need.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A non-transitory computer readable storage medium for causing a computer monitoring a power distribution system in which a first customer and a second customer are mixed to execute a process, the process comprising:
acquiring first data measured with a first measurement device installed in the first customer, the first measurement device measuring the first data about an electric power at a first time interval;
acquiring second data measured with a second measurement device installed in the second customer, the second measurement device measuring the second data about an electric power at a second time interval longer than the first time interval;
estimating data of the first time interval about an electric power of the second customer by using the acquired first data and the acquired second data; and
estimating a value about a voltage or a current for each of the first customer and the second customer by using the estimated data of the first time interval and the acquired first data.
2. The non-transitory computer readable storage medium as claimed in claim 1, wherein
the estimating the data of the first time interval includes normalizing the acquired first data, and estimating the data of the first time interval by using the normalized first data and the acquired second data.
3. The non-transitory computer readable storage medium as claimed in claim 2, wherein
the estimating the data of the first time interval includes selecting a plurality of normalized first data, and estimating the data of the first time interval multiple times by using the selected normalized first data and the acquired second data,
the estimating the value about the voltage or the current for each of the first customer and the second customer includes estimating a probability distribution of a voltage value or a current value for each of the first customer and the second customer by using the plurality of estimated data of the first time interval and the acquired first data.
4. The non-transitory computer readable storage medium as claimed in claim 3, wherein
when the plurality of normalized first data are selected, the estimating the data of the first time interval includes selecting the plurality of normalized first data from all the normalized first data corresponding to the first customer having a common characteristic with the second customer.
5. An estimation apparatus monitoring a power distribution system in which a first customer and a second customer are mixed, the estimation apparatus comprising:
a first acquisition unit that acquires the first data measured with a first measurement device installed in the first customer, the first measurement device measuring the first data about an electric power at a first time interval;
a second acquisition unit that acquires the second data measured with a second measurement device installed in the second customer, the second measurement device measuring the second data about an electric power at a second time interval longer than the first time interval;
a first estimation unit that estimates data of the first time interval about an electric power of the second customer by using the acquired first data; and
a second estimation unit that estimates a value about a voltage or a current for each of the first customer and the second customer by using the estimated data of the first time interval and the acquired first data.
6. The estimation apparatus as claimed in claim 5, wherein
the first estimation unit normalizes the acquired first data, and estimates the data of the first time interval by using the normalized first data and the acquired second data.
7. The estimation apparatus as claimed in claim 6, wherein
the first estimation unit selects a plurality of normalized first data, and estimates the data of the first time interval multiple times by using the selected normalized first data and the acquired second data,
the second estimation unit estimates a probability distribution of a voltage value or a current value for each of the first customer and the second customer by using the plurality of data of the first time interval estimated by the first estimation unit and the first data acquired by the first acquisition unit.
8. The estimation apparatus as claimed in claim 7, wherein
when the plurality of normalized first data are selected, the first estimation unit selects the plurality of normalized first data from all the normalized first data corresponding to the first customer having a common characteristic with the second customer.
9. An estimation method for causing a computer monitoring a power distribution system in which a first customer and a second customer are mixed to execute a process, the process comprising:
acquiring first data measured with a first measurement device installed in the first customer, the first measurement device measuring the first data about an electric power at a first time interval;
acquiring second data measured with a second measurement device installed in the second customer, the second measurement device measuring the second data about an electric power at a second time interval longer than the first time interval;
estimating data of the first time interval about an electric power of the second customer by using the acquired first data and the acquired second data; and
estimating a value about a voltage or a current for each of the first customer and the second customer by using the estimated data of the first time interval and the acquired first data.
10. The estimation method as claimed in claim 9, wherein
the estimating the data of the first time interval includes normalizing the acquired first data, and estimating the data of the first time interval by using the normalized first data and the acquired second data.
11. The estimation method as claimed in claim 10, wherein
the estimating the data of the first time interval includes selecting a plurality of normalized first data, and estimating the data of the first time interval multiple times by using the selected normalized first data and the acquired second data,
the estimating the value about the voltage or the current for each of the first customer and the second customer includes estimating a probability distribution of a voltage value or a current value for each of the first customer and the second customer by using the plurality of estimated data of the first time interval and the acquired first data.
12. The estimation method as claimed in claim 11, wherein
when the plurality of normalized first data are selected, the estimating the data of the first time interval includes selecting the plurality of normalized first data from all the normalized first data corresponding to the first customer having a common characteristic with the second customer.